INCR (Intercure) Moat Score: 3/10 (As of Sep. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INCR Intercure Ltd INCR
67 GF Score
Price $5.34
GF Value $6.18
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Intercure Moat Score?

Intercure INCR -2.95% 67 Moat Score is 3 as of Sep. 04, 2026. GuruFocus rates INCR with a GF Score™ of 67/100 and a GF Value™ of $6.18 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,026 Drug Manufacturers companies, Intercure ranks better than 86.06% on this metric.

Intercure has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Intercure has No Moat: Intercure Ltd operates in the cannabis industry, which is characterized by regulatory challenges and intense competition. It lacks significant market share, brand strength, or proprietary technology to establish a durable competitive advantage.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Intercure might have No Moat - Very weak/transient advantages.

Intercure  (NAS:INCR) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Intercure Moat Score Related Terms

INCR vs CTOR, ZYBT, TLPH: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Intercure's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Intercure Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Intercure's Moat Score distribution charts can be found below:

* The bar in red indicates where Intercure's Moat Score falls into.


INCR
67GF Score
Intercure Ltd INCR
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Intercure (INCR) has a Moat Score of 3 as of Sep. 04, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Intercure ranks #143 out of 1026 companies in the Drug Manufacturers industry, placing it in the top 13.9%.
Is Intercure's Moat Score too high?
Intercure's current Moat Score is 3. Based on the distribution chart, Intercure ranks #143 out of 1026 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Intercure has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Intercure's Moat Score compare to CTOR and ZYBT?
According to the Drug Manufacturers industry distribution chart, Intercure ranks #143 out of 1026 companies for Moat Score. This places Intercure in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Intercure's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intercure stock overvalued right now?
Based on GuruFocus' analysis, Intercure (INCR) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.18, compared to a current price of $5.34 — trading 13.7% below its estimated fair value. The current Moat Score is 3. Intercure's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Intercure (INCR), the current Moat Score is 3 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Intercure (INCR) Overvalued in 2026?

Based on GuruFocus' analysis, Intercure stock appears to be undervalued. The current stock price of $5.34 is trading 13.7% below its estimated GF Value™ of $6.18. GuruFocus considers Intercure to be Modestly Undervalued.

Key valuation signals for INCR:

  • Moat Score: 3
  • GF Value™: $6.18 vs. price of $5.34 (13.7% below fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the INCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Intercure Business Description

Other Exchanges INCR:Israel
Address 85 Medinat ha-Yehudim Street, Herzliya, ISR, 4676670
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
67GF Score

Get the complete analysis for INCR

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.34
Price
$6.18
GF Value